In PNAS this week: innate immune interactions with TB bug, cytoplasmic microtubule organizing center-like structure, and more.
The Ultra's combination of a lower limit of detection and ability to find dead bacilli after starting TB therapy vastly improves sensitivity compared to other tests, the study’s authors said.
Variants in and around inflammation-related gene CD53 were linked to TB in older Thai individuals infected with certain Mycobacterium tuberculosis lineages.
The study is the first to demonstrate the design features and operational characteristics of Cepheid's Xpert MTB/RIF Ultra assay.
The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
A UK-led international consortium is sequencing tuberculosis genomes and cataloguing drug resistance mutations to enable more rapid NGS-based diagnostics.
The agreement with Mexico's agriculture department covers studies to evaluate molecular detection assays for bovine TB, as well as studies on zoonotic TB diagnosis.
In Genome Biology this week: Mycobacterium tuberculosis population dynamics, mapping precision in GWAS, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.